Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Seattle Genetics Inc and Subsidiary of Astellas Pharma Inc Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration


Thursday, 27 Jun 2013 08:00pm EDT 

Seattle Genetics, Inc. and Agensys, Inc., a subsidiary Astellas Pharma Inc. announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies' existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME. 

Company Quote

1606.0
-28.0 -1.71%
10:09pm EDT